LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Layered learning: Eight precepting strategies for the new attending pharmacist.

Guidry, Corey M / Jackson, Brittany T / Hawkins, W Anthony

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

2022 Volume 80, Issue 7, Page(s) 407–411

MeSH term(s)	Humans ; Pharmacists ; Learning ; Education, Pharmacy ; Preceptorship ; Students, Pharmacy ; Problem-Based Learning
Language	English
Publishing date	2022-11-19
Publishing country	England
Document type	Journal Article
ZDB-ID	1224627-x
ISSN	1535-2900 ; 1079-2082
ISSN (online)	1535-2900
ISSN	1079-2082
DOI	10.1093/ajhp/zxac382
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 419: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Kimyrsa and Orbactiv - A Tale of Two Formulations.

Jackson, Brittany T / Cluck, David B / Henao-Martínez, Andrés F / Chastain, Daniel B

Drug design, development and therapy

2023 Volume 17, Page(s) 737–742

Abstract: Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a ... ...

Abstract	Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a similar pharmacokinetic and microbiologic profile. At present, the NF lacks significant real-world experience relative to other available lipoglycopeptides and thus its place in therapy remains difficult to predict but would not be expected to be significantly different than its OF.
MeSH term(s)	Lipoglycopeptides ; Anti-Bacterial Agents/pharmacokinetics ; Glycopeptides ; Vancomycin
Chemical Substances	oritavancin (PUG62FRZ2E) ; Lipoglycopeptides ; Anti-Bacterial Agents ; Glycopeptides ; Vancomycin (6Q205EH1VU)
Language	English
Publishing date	2023-03-09
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2451346-5
ISSN	1177-8881 ; 1177-8881
ISSN (online)	1177-8881
ISSN	1177-8881
DOI	10.2147/DDDT.S324285
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Managing Modern Antiretroviral Therapy in the Intensive Care Unit: Overcoming Challenges for Critically Ill People With Human Immunodeficiency Virus.

Chastain, Daniel B / Tu, Patrick J / Brizzi, Marisa / Keedy, Chelsea A / Baker, Aubrey N / Jackson, Brittany T / Ladak, Amber F / Hamilton, Leslie A / Sells, Nicholas R / Henao-Martínez, Andrés F / McManus, Kathleen A / Cluck, David B

Open forum infectious diseases

2024 Volume 11, Issue 5, Page(s) ofae213

Abstract: People with human immunodeficiency virus (HIV) have a 50% excess risk for intensive care unit (ICU) admission, often for non-HIV-related conditions. Despite this, clear guidance for managing antiretroviral therapy (ART) in this setting is lacking. ... ...

Abstract	People with human immunodeficiency virus (HIV) have a 50% excess risk for intensive care unit (ICU) admission, often for non-HIV-related conditions. Despite this, clear guidance for managing antiretroviral therapy (ART) in this setting is lacking. Selecting appropriate ART in the ICU is complex due to drug interactions, absorption issues, and dosing adjustments. Continuing ART in the ICU can be challenging due to organ dysfunction, drug interactions, and formulary limitations. However, with careful consideration, continuation is often feasible through dose adjustments or alternative administration methods. Temporary discontinuation of ART may be beneficial depending on the clinical scenario. Clinicians should actively seek resources and support to mitigate adverse events and drug interactions in critically ill people with HIV. Navigating challenges in the ICU can optimize ART and improve care and outcomes for critically ill people with HIV. This review aims to identify strategies for addressing the challenges associated with the use of modern ART in the ICU.
Language	English
Publishing date	2024-04-17
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofae213
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The cellular antioxidant and anti-glycation capacities of phenolics from Georgia peaches

Liao, Xiaoxi / Brock, Andrew A / Jackson, Brittany T / Greenspan, Phillip / Pegg, Ronald B

Food chemistry. 2020 June 30, v. 316

2020

Abstract: Plant-based polyphenolics have been reported to bestow health benefits when consumed, which are partially ascribed to their antioxidant activity. Yet, many current in vitro chemical assays to characterize antioxidant potential do not truly reflect the ... ...

Abstract	Plant-based polyphenolics have been reported to bestow health benefits when consumed, which are partially ascribed to their antioxidant activity. Yet, many current in vitro chemical assays to characterize antioxidant potential do not truly reflect the physiological properties of food antioxidants in vivo. The present study employed biological approaches, including a cellular antioxidant activity (CAA) and protein glycation assays, to offer an improved picture of antioxidant potential of phenolic extracts from Georgia peach cultivars. The phenolic extracts from two peach varieties, showing contrasting antioxidant capacities according to hydrophilic-oxygen radical absorbance capacity (H-ORACFL) and ferric reducing antioxidant power (FRAP) assays, exhibited significant differences in two biological tests when the assays were performed on a fresh weight basis. The procyanidins fraction displayed notable antioxidant capacity, when compared to other phenolic classes in the peach extract, in these two biologically relevant assays.
Keywords	Prunus persica ; absorbance ; antioxidant activity ; antioxidants ; bioassays ; cultivars ; fruit extracts ; glycation ; peaches ; procyanidins ; Georgia
Language	English
Dates of publication	2020-0630
Publishing place	Elsevier Ltd
Document type	Article
ZDB-ID	243123-3
ISSN	1873-7072 ; 0308-8146
ISSN (online)	1873-7072
ISSN	0308-8146
DOI	10.1016/j.foodchem.2020.126234
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 3634: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: The cellular antioxidant and anti-glycation capacities of phenolics from Georgia peaches.

Liao, Xiaoxi / Brock, Andrew A / Jackson, Brittany T / Greenspan, Phillip / Pegg, Ronald B

Food chemistry

2020 Volume 316, Page(s) 126234

Abstract	Plant-based polyphenolics have been reported to bestow health benefits when consumed, which are partially ascribed to their antioxidant activity. Yet, many current in vitro chemical assays to characterize antioxidant potential do not truly reflect the physiological properties of food antioxidants in vivo. The present study employed biological approaches, including a cellular antioxidant activity (CAA) and protein glycation assays, to offer an improved picture of antioxidant potential of phenolic extracts from Georgia peach cultivars. The phenolic extracts from two peach varieties, showing contrasting antioxidant capacities according to hydrophilic-oxygen radical absorbance capacity (H-ORAC
MeSH term(s)	Antioxidants/chemistry ; Antioxidants/pharmacology ; Caco-2 Cells ; Georgia ; Humans ; Phenols/chemistry ; Proanthocyanidins/chemistry ; Prunus persica/chemistry
Chemical Substances	Antioxidants ; Phenols ; Proanthocyanidins
Language	English
Publishing date	2020-01-23
Publishing country	England
Document type	Journal Article
ZDB-ID	243123-3
ISSN	1873-7072 ; 0308-8146
ISSN (online)	1873-7072
ISSN	0308-8146
DOI	10.1016/j.foodchem.2020.126234
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 3634: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy.

Chastain, Daniel B / White, Bryan P / Tu, Patrick J / Chan, Sophea / Jackson, Brittany T / Kubbs, Kara A / Bandali, Aiman / McDougal, Steven / Henao-Martínez, Andrés F / Cluck, David B

The Annals of pharmacotherapy

2023 Volume 58, Issue 3, Page(s) 305–321

Abstract: Objective: To provide updates on the epidemiology and recommendations for management of candidemia in patients with critical illness.: Data sources: A literature search using the PubMed database (inception to March 2023) was conducted using the ... ...

Abstract	Objective: To provide updates on the epidemiology and recommendations for management of candidemia in patients with critical illness. Data sources: A literature search using the PubMed database (inception to March 2023) was conducted using the search terms "invasive candidiasis," "candidemia," "critically ill," "azoles," "echinocandin," "antifungal agents," "rapid diagnostics," "antifungal susceptibility testing," "therapeutic drug monitoring," "antifungal dosing," "persistent candidemia," and "Candida biofilm." Study selection/data extraction: Clinical data were limited to those published in the English language. Ongoing trials were identified through ClinicalTrials.gov. Data synthesis: A total of 109 articles were reviewed including 25 pharmacokinetic/pharmacodynamic studies and 30 studies including patient data, 13 of which were randomized controlled clinical trials. The remaining 54 articles included fungal surveillance data, in vitro studies, review articles, and survey data. The current 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Management of Candidiasis provides recommendations for selecting empiric and definitive antifungal therapies for candidemia, but data are limited regarding optimized dosing strategies in critically ill patients with dynamic pharmacokinetic changes or persistent candidemia complicated. Relevance to patient care and clinical practice: Outcomes due to candidemia remain poor despite improved diagnostic platforms, antifungal susceptibility testing, and antifungal therapy selection for candidemia in critically ill patients. Earlier detection and identification of the species causing candidemia combined with recognition of patient-specific factors leading to dosing discrepancies are crucial to improving outcomes in critically ill patients with candidemia. Conclusions: Treatment of candidemia in critically ill patients must account for the incidence of non-albicans
MeSH term(s)	Adult ; Humans ; Candidemia/diagnosis ; Candidemia/drug therapy ; Candidemia/epidemiology ; Antifungal Agents/pharmacology ; Antifungal Agents/therapeutic use ; Critical Illness ; Echinocandins/pharmacology ; Echinocandins/therapeutic use ; Candida ; Intensive Care Units ; Microbial Sensitivity Tests
Chemical Substances	Antifungal Agents ; Echinocandins
Language	English
Publishing date	2023-06-05
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1101370-9
ISSN	1542-6270 ; 1060-0280
ISSN (online)	1542-6270
ISSN	1060-0280
DOI	10.1177/10600280231175201
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 900: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Characteristics and Outcomes of Cryptococcosis among Patients with and without COVID-19.

Chastain, Daniel B / Kung, Vanessa M / Vargas Barahona, Lilian / Jackson, Brittany T / Golpayegany, Sahand / Franco-Paredes, Carlos / Thompson, George R / Henao-Martínez, Andrés F

Journal of fungi (Basel, Switzerland)

2022 Volume 8, Issue 11

Abstract: The effect of COVID-19 on the risk and prognosis of cryptococcosis is unclear. We compared the characteristics and outcomes of cryptococcosis in patients with and without COVID-19. Patients 18 years and older with cryptococcosis were identified from ... ...

Abstract	The effect of COVID-19 on the risk and prognosis of cryptococcosis is unclear. We compared the characteristics and outcomes of cryptococcosis in patients with and without COVID-19. Patients 18 years and older with cryptococcosis were identified from TriNetX and separated into two cohorts based on a diagnosis of COVID-19 within 3 months of the index diagnosis of cryptococcosis. Differences examined between groups included comorbidities, immunosuppressive medications, ED visits, hospitalizations, ICU admissions, mechanical ventilation, and deaths. The propensity score matching was performed based on demographics and comorbidities. Of the 6998 patients with cryptococcosis included, 4.4% (n = 306) had COVID-19 prior to cryptococcosis. Mortality was higher in patients with COVID-19 compared to those without COVID-19 (14% vs. 11%, p = 0.032). Additionally, those with COVID-19 were older (55.2 ± 14.4 vs. 51.9 ± 15.2 years, p < 0.001) with higher rates of transplant (29% vs. 13%, p < 0.001), neoplastic disease (37% vs. 21%, p < 0.001), chronic kidney disease (42% vs. 18%, p < 0.001), or diabetes (35% vs. 19%, p < 0.001) but not HIV (30% vs. 31%, p = 0.618). Glucocorticoid use was more common in those with COVID-19 (52% vs. 27%, p < 0.001). More patients with COVID-19 required ED visits (29% vs. 23%, p = 0.025) and ICU admission (18% vs. 11%, p < 0.001). After propensity score matching, patients with COVID-19 had higher rates of neoplastic disease, heart failure, chronic kidney disease, and glucocorticoid use but did not experience worse outcomes compared to those without COVID-19. Patients with COVID-19 who developed cryptococcosis had independently higher rates of comorbidities and glucocorticoid use but similar outcomes, including death, versus those without COVID-19.
Language	English
Publishing date	2022-11-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2784229-0
ISSN	2309-608X ; 2309-608X
ISSN (online)	2309-608X
ISSN	2309-608X
DOI	10.3390/jof8111234
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: a case report and literature review.

Chastain, Daniel B / Golpayegany, Sahand / Henao-Martínez, Andrés F / Jackson, Brittany T / Stoudenmire, Laura Leigh / Bell, Kaye / Stover, Kayla R / Franco-Paredes, Carlos

Therapeutic advances in infectious disease

2022 Volume 9, Page(s) 20499361221112639

Abstract: While overall survival with multiple myeloma (MM) has improved, patients suffer from overwhelming tumor burden, MM-associated comorbidities, and frequent relapses requiring administration of salvage therapies. As a result, this vicious cycle is often ... ...

Abstract	While overall survival with multiple myeloma (MM) has improved, patients suffer from overwhelming tumor burden, MM-associated comorbidities, and frequent relapses requiring administration of salvage therapies. As a result, this vicious cycle is often characterized by cumulative immunodeficiency stemming from a combination of disease- and treatment-related factors leading to neutropenia, T-cell deficiency, and hypogammaglobulinemia. Infectious etiologies differ based on the duration of MM and treatment-related factors, such as number of previous treatments and cumulative dose of corticosteroids. Herein, we present the case of a patient who was receiving pomalidomide without concomitant corticosteroids for MM and was later found to have cryptococcosis, as well as findings from a literature review. Most cases of cryptococcosis are reported in patients with late-stage MM, as well as those receiving novel anti-myeloma agents, such as pomalidomide, in combination with corticosteroids or following transplantation. However, it is likely cryptococcosis may be underdiagnosed in this population. Due to the cumulative immunodeficiency present in patients with MM, clinicians must be suspicious of cryptococcosis at any stage of MM.
Language	English
Publishing date	2022-07-23
Publishing country	England
Document type	Case Reports
ZDB-ID	2728410-4
ISSN	2049-937X ; 2049-9361
ISSN (online)	2049-937X
ISSN	2049-9361
DOI	10.1177/20499361221112639
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study.

Chastain, Daniel B / Kung, Vanessa M / Golpayegany, Sahand / Jackson, Brittany T / Franco-Paredes, Carlos / Vargas Barahona, Lilian / Thompson, George R / Henao-Martínez, Andrés F

Mycoses

2022 Volume 65, Issue 8, Page(s) 815–823

Abstract: It is unclear if there is an association between COVID-19 and cryptococcosis. Therefore, this study aimed to describe the clinical features, risk factors, and outcomes associated with cryptococcosis in hospitalised patients with COVID-19. The objectives ... ...

Abstract	It is unclear if there is an association between COVID-19 and cryptococcosis. Therefore, this study aimed to describe the clinical features, risk factors, and outcomes associated with cryptococcosis in hospitalised patients with COVID-19. The objectives of this study were to determine the incidence of and examine factors associated with cryptococcosis after a diagnosis of COVID-19. We used TriNetX to identify and sort patients 18 years and older hospitalised with COVID-19 into two cohorts based on the presence or absence of a diagnosis of cryptococcosis following diagnosis of COVID-19. Outcomes of interest included the incidence of cryptococcosis following the diagnosis of COVID-19 as well as the proportion of patients in each group who had underlying comorbidities, received immunomodulatory therapy, required ICU admission or mechanical ventilation (MV), or died. Propensity score matching was used to adjust for confounding. Among 212,479 hospitalised patients with COVID-19, 65 developed cryptococcosis. The incidence of cryptococcosis following COVID-19 was 0.022%. Patients with cryptococcosis were more likely to be male and have underlying comorbidities. Among cases, 32% were people with HIV. Patients with cryptococcosis were more likely to have received tocilizumab (p < .0001) or baricitinib (p < .0001), but not dexamethasone (p = .0840). ICU admission (38% vs 29%), MV (23% vs 11%), and mortality (36% vs 14%) were significantly higher among patients with cryptococcosis. Mortality remained elevated after adjusted propensity score matching. Cryptococcosis occurred most often in hospitalised patients with COVID-19 who had traditional risk factors, comparable to findings in patients without COVID-19. Cryptococcosis was associated with increased ICU admission, MV, and mortality.
MeSH term(s)	COVID-19/epidemiology ; Cryptococcosis/drug therapy ; Cryptococcosis/epidemiology ; Female ; Hospitalization ; Humans ; Male ; Respiration, Artificial ; SARS-CoV-2
Language	English
Publishing date	2022-06-19
Publishing country	Germany
Document type	Journal Article ; Multicenter Study
ZDB-ID	392487-7
ISSN	1439-0507 ; 0933-7407
ISSN (online)	1439-0507
ISSN	0933-7407
DOI	10.1111/myc.13476
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.176: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito